Abstract: A method and apparatus for agnostic PPPoE switching is described. A method in a network element comprises converting Point to Point Protocol (PPP) protocol data units (PDUs) encapsulated according to different protocols into PPP PDUs with a uniform encapsulation, and transmitting the uniformly encapsulated PPP PDUs.

Abstract: Context selection in a network element through subscriber flow switching. According to one embodiment of the invention, authentication, authorization and accounting is performed for a subscriber desiring to connect to a plurality of services on different contexts. In response, bindings are established to a plurality of contexts for the subscriber. In response to receiving a traffic packet from the subscribed, at least certain header information from the traffic packet is accessed. Based on at least the accessed header information, one of the plurality of contexts is selected for that traffic packet.

Abstract: An airline may offer two procedures for redeeming frequent flier miles for tickets on a specified flight of that airline, with one procedure available to frequent flier program members that do not have transactional cards associated with the frequent flier program, and another redemption procedure available to frequent flier program members that have a transactional card associated with the frequent flier program. Cardmembers have improved award seat availability for frequent flier mile redemption, regardless of their status in the frequent flier program. Cardmembers are provided with last seat availability at a base redemption rate. Thus, cardmembers are not subject to limited award seat capacity controls and restrictions that airline frequent flier programs have in place, and cardmembers do not have to use higher redemption rates for last seat availability.

Abstract: A bar-b-que grill comprising: a front wall; a first side wall in communication with the front wall; a rear wall in communication with the first side wall; a second side wall in communication with the front wall and the rear wall; a first slot located in the first side wall; a second slot located in the second side wall; a first U shaped rail in communication with the front wall, with an opening of the U facing towards the rear wall; a second U shaped rail in communication with the rear wall, with an opening of the U facing towards the front wall; at least one heat deflector plate, wherein the first and second U shaped rails are configured to allow the at least one heat deflector plate to slide along the first and second U shaped rails into and out of the bar-b-que grill via at least one of the first and second slots.

Abstract: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit 5 HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

Abstract: In a CDR (clock data recovery) deserializer, a clock divider receives a recovered clock signal (SCLK) and generates a divided clock signal (RPCLK). The frequency of the divided clock signal is lowered with each cycle of the divided clock signal being generated for each count of cycles of the recovered clock signal up to a predetermined ratio number. A serial-to-parallel shift register shifts in recovered serial data bits with each cycle of the recovered clock signal and outputs the predetermined ratio number of the shifted recovered serial data bits at a predetermined transition of every cycle of the divided clock signal. A SYNC (synchronization) detect logic asserts a VRS (diVider ReSet) signal coupled to the clock divider for controlling the clock divider to generate the predetermined transition for a cycle of the divided clock signal when the VRS signal is asserted.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: Methods are provided for identifying anti-HIV therapeutic compounds substituted with carboxyl ester or phosphonate ester groups. Libraries of such compounds are screened optionally using the novel enzyme GS-7340 Ester Hydrolase. Compositions and methods relating to GS-7340 Ester Hydrolase also are provided.

Abstract: Phosphonate substituted compounds with HIV protease inhibitory properties having use as therapeutics and for other industrial purposes are disclosed. The compositions inhibit HIV protease activity and/or are useful therapeutically for the treatment of AIDS and other antiviral infections, as well as in assays for the detection of HIV protease.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: A novel method has led to the identification of novel mixed ester-amidates of PMPA for retroviral or hepadnaviral therapy, including compounds of structure (5a) having substituent groups as defined herein. Compositions of these novel compounds in pharmaceutically acceptable excipients and their use in therapy and prophylaxis are provided.

Abstract: A method and apparatus for providing domainless service selection (DLSS) are described. According to one embodiment of the invention, there is a service selection network element used to provide access of computing devices to a set of one or more services provided by a set of one or more providers. In addition, a web portal allows subscribers to log in and/or select/switch between the services and providers. Responsive to such action by a given subscriber, the web portal causes a record of that subscriber to be altered to reflect the action and causes the service selection network element to attempt to connect the subscriber accordingly. According to certain embodiments of the invention, subscribers' domainless user identifiers are merged by the service selection network element with domain names (stored in a database) of services/providers to form network addresses (e.g., Internet addresses).

Abstract: Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a &bgr;-dicarbonyl enol ether leaving group.

Abstract: A portable toilet for marine craft securely located on the deck of a boat, and including a privacy cover. The toilet includes a seat assembly and a box-shaped housing for a portable toilet. A support brace connects the boat seat assembly to the housing. The boat seat assembly includes a boat seat, a boat seat back, and the support brace, made up of first and second support members hinged together. The first member connects the boat seat back to the second support member. The inner surface of the second support member defines a seat receiving portion for the boat seat. The portable marine privacy toilet can also have a swivel attached to the bottom for allowing the toilet to be vertically pivoted, and a clamp for removably fastening the privacy cover to the toilet.

Abstract: Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a .beta.-dicarbonyl enol ether leaving group.

Abstract: Cysteine protease inhibitors which deactivate the protease by covalently bonding to the cysteine protease and releasing the enolate of a 1,3-dicarbonyl (or its enolic form). The cysteine protease inhibitors of the present invention accordingly comprise a first portion which targets a desired cysteine protease and positions the inhibitor near the thiolate anion portion of the active site of the protease, and a second portion which covalently bonds to the cysteine protease and irreversibly deactivates that protease by providing a carbonyl or carbonyl-equivalent which is attacked by the thiolate anion of the active site of the cysteine protease to sequentially cleave a .beta.-dicarbonyl enol ether leaving group.